This is a discovery that might significantly improve the fight once morest breast cancer.
In Spain, Dr. Javier Cortés, director of the International Breast Cancer Center in Barcelona (IBCC) has published the conclusions of the “most positive study in the history” of breast cancer.
This trial, published in the New England Journal of Medicine, tested the safety and efficacy of the drug “trastuzumab deruxtecan” in patients with HER2-positive metastatic breast cancer.
Objective ? Prove that this drug provides an answer in the fight once morest this particularly aggressive type of cancer, as reported by L’Indépendant.
“We are convinced that trastuzumab deruxtecan can bring a profound change in the treatment of so-called HER2 positive breast and gastric cancers, a genetic mutation producing a protein that boosts the proliferation of cancer cells”, underlined the boss of the AstraZeneca group, Pascal Soriot.
What is it regarding ? This drug combines a targeted drug with another chemotherapy drug (deruxtecan).
“Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower in those who received trastuzumab deruxtecan than in those who received trastuzumab emtansine”, summarizes the study.
Thus, the results obtained with this drug have been “so positive” that trastuzumab deruxtecan is now establishing itself as the new standard of second-line treatment for patients with HER2-positive breast cancer.
